# XPhyto Therapeutics to acquire 3a-diagnostics GmbH

XPhyto Therapeutics Corp. signed a definitive agreement to acquire 3a-diagnostics GmbH for EUR 3.9 million. The acquisition is planned to close on or around October 31, 2021.

- Type: Acquisition
- Announced: 2021-07-20
- Where: Frickenhausen, Germany, Germany
- Value: $4.60M (3.90M EUR)
- Status: announced
- Products: biosensor tests, PCR test COVID-ID Lab
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [XPhyto Therapeutics Corp.](https://endata.com/companies/56593.md) (acquirer)
- [3a-diagnostics GmbH](https://endata.com/companies/56594.md) (target)

## Sources

- [biospace.com](https://www.biospace.com/xphyto-signs-transformative-acquisition-agreement-with-3a-diagnostics-to-enter-hi-tech-biosensor-market-and-expand-its-diagnostic-product-portfolio), 2021-07-20: "We strongly believe that this acquisition will result in powerful synergies and further feed XPhyto's diagnostic pipeline, supporting our long-term commercial growth plans."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.